ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PVLA / options
LKFT (57) IMNM (26) SEPN (63) SDGR (53) ⌘ Pro Terminal →

Palvella Therapeutics Inc. (PVLA) Options Positioning, Max Pain & Unusual Sweeps

$146.33 +0.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $146.08

Palvella Therapeutics Inc. (PVLA) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.11B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PVLA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PVLA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Palvella Therapeutics Inc. (NASDAQ: PVLA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $146.33 (+0.12% 1D, market cap $2.11B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PVLA ranks #360 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PVLA compare to LKFT and IMNM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PVLA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.9%. By comparison, LKFT (Lakefront Biotherapeutics) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $2.13B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.15B). Among the 5-stock peer group, PVLA leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PVLA?
▼

Per PVLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001583648), Palvella Therapeutics Inc. generated $108.1M in revenue (+173.9% YoY), -$41.7M in net income, and -$25.0M in free cash flow against $59.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $146.08 (-0.17%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (7)Whales (15)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$169 Bull$138 Base$107 Bear
📬 FREE PVLA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PVLA)Realized 20D OHLCV Swing Band: ±11.9%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY PVLA SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (33% of score)

20D Institutional Volume Accumulation (±11.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$128.51-3.6% Next Q
Q2 (-2Q)
40
Grade D$123.92+7.3% Next Q
Q3 (-1Q)
42
Grade D$132.91+10.1% Next Q
Current
45
Grade D$146.33-6.3% Hist 90D α
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PVLA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PVLA currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($141.67) and Max Pain ($153.65) forces dealer call-delta covering toward $169.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PVLA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PVLA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±11.9%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PVLA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PVLA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PVLA)

  • ✓Walkthrough of PVLA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PVLA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.67%📐 HORIZONTAL RANGE
2026-11-03O $151.6H $151.6L $146.2C $146.3VOL 293.1K
RES: $160.6SUP: $114.3SMA50: $141.7SMA200: $127.4
$166.6$144.9$123.1$101.3$79.59RES $160.6SUP $114.3$146.32026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PVLA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PVLA Butterfly Map → + Track PVLA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +173.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PVLA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PVLA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PVLA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PVLA)

Health Care Rank #360 of 1015 ⚔️ LKFT vs PVLA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PVLA vs. LKFT, IMNM, SEPN, SDGR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Palvella Therapeutics Inc. (PVLA) ranks #360 by composite RQD confidence (45/100, grade D) and #246 by equity capitalization ($2.11B). Within this direct 5-issuer industry benchmark cohort, PVLA leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PVLA at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PVLA ACTIVE
Palvella Therapeutics Inc.
D 45/100 — — -27.9% +0.12% $2.11B Benchmark Subject
LKFT
Lakefront Biotherapeutics
D+ 57/100 — — — -0.80% $2.13B /lkft-vs-pvla →
IMNM
Immunome Inc.
E 26/100 — — -35.0% +7.58% $2.15B /imnm-vs-pvla →
SEPN
Septerna Inc.
C 63/100 — — -20.7% -1.82% $2.05B /sepn-vs-pvla →
SDGR
Schrodinger Inc.
D+ 53/100 — 55.7% -35.0% -3.50% $2.03B /sdgr-vs-pvla →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001583648 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Palvella Therapeutics Inc. (PVLA) reported GAAP revenue of $108.1M (+173.9% vs. FY2024 revenue of $39.5M , and +152.5% cumulative change since FY2023) , GAAP net income of -$41.7M, operating cash flow of -$25.0M, and free cash flow of -$25.0M (-130.7% YoY). On the balance sheet, PVLA closed FY2025 with $59.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $108.1M -$41.7M -$25.0M -$25.0M $59.6M —
FY2024 (FY) 2024-12-31 $39.5M -$17.4M -$10.8M -$10.8M $88.2M —
FY2023 (FY) 2023-12-31 $42.8M $18.7M -$13.7M -$13.7M — —

3. PVLA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PVLA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Palvella Therapeutics Inc. (NASDAQ: PVLA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $146.33 (+0.12% 1D, market cap $2.11B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PVLA ranks #360 in composite RQD confidence.

How does PVLA compare to LKFT and IMNM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PVLA carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.9%. By comparison, LKFT (Lakefront Biotherapeutics) holds a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $2.13B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.15B). Among the 5-stock peer group, PVLA leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PVLA?

Per PVLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001583648), Palvella Therapeutics Inc. generated $108.1M in revenue (+173.9% YoY), -$41.7M in net income, and -$25.0M in free cash flow against $59.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PVLA trading relative to its 50-day, 200-day, and 52-week technical levels?

PVLA last traded at $146.33 (+0.12% on volume of 303,480 shares), positioning the stock +3.29% above its 50-day simple moving average ($141.67) and +14.86% above its 200-day simple moving average ($127.40). Across its 52-week range of $71.55 to $161.38, PVLA sits at the 83.2% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.9% ($128.92 to $163.74).

Direct Sub-Reports: PVLA RQD Cockpit PVLA 12M Forecast PVLA Earnings & Move PVLA Dividends & DRIP PVLA Insiders & 13F PVLA Whale Options PVLA Profit Sankey PVLA News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

PVLA — Palvella Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Palvella Therapeutics Inc. (PVLA) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $146.33 (+0.12% 1D, market capitalization $2.11B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -27.9%, gross margin of —, operating margin of —, and free cash flow yield of -1.14%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Palvella Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B.8M for FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Palvella Therapeutics Inc. (PVLA) reported $108.1M in annual revenue (up from $39.5M in FY2024, +173.9% YoY) and -$41.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($42.8M revenue, $18.7M net income) through FY2025, PVLA scaled operating cash flow to -$25.0M and free cash flow to -$25.0M, backed by $59.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -1.14% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $71.55 – $161.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. Sector correlation data beyond the Beta of 1.0 is not provided. Investors should watch the FDA review timeline referenced in the catalyst news, since that item is the only forward-dated event in the source data.

  • Key Question #1: Can PVLA sustain or expand its — operating margin and -27.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $108.1M and free cash flow of -$25.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PVLA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PVLA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Palvella Therapeutics Inc. (PVLA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PVLA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PVLA Bull vs. Bear Conversation Board — What's Your Call at $146.33?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PVLA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PVLA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $181.23 (+24.0%)
📌 Pinned Debate

Institutional whale 13F flow scores 17 of 20 and a GREEN-flagged FDA priority review gives a near-term catalyst.

Here is why I am bullish on PVLA here at $146.15: Institutional whale 13F flow scores 17 of 20 and a GREEN-flagged FDA priority review gives a near-term catalyst.. Compare PVLA's 0.0% operating margin and -27.9% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $138.84 are getting bought.

CapAlloc_Nerd 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $112.54 (-23.0%)
Spot @ $146.15

Negative ROIC of -27.9%, negative FCF in all reported periods, and a 3 of 20 insider conviction score point to weak fundamentals and di

I respect the product at Palvella Therapeutics Inc., but the stock at $146.15 is a different story. Negative ROIC of -27.9%, negative FCF in all reported periods, and a 3 of 20 insider conviction score point to weak fundamentals and distribution risk.. FCF yield is -1.14% and RQD sits at 45/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%